TF Capital

Avenzo Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative therapies for oncology, specifically targeting underserved and rare cancers. The company operates a specialized platform that focuses on creating novel treatments aimed at genomically defined cancer types. By prioritizing targeted therapies, Avenzo Therapeutics seeks to advance cancer treatment options for patients who may not have access to effective solutions, thus addressing significant gaps in the current therapeutic landscape.

Avenzo Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative therapies for oncology, specifically targeting underserved and rare cancers. The company operates a specialized platform that focuses on creating novel treatments aimed at genomically defined cancer types. By prioritizing targeted therapies, Avenzo Therapeutics seeks to advance cancer treatment options for patients who may not have access to effective solutions, thus addressing significant gaps in the current therapeutic landscape.

Sanegene Bio is a biotechnology company focused on developing RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. Its innovative RNAi drug discovery platform targets disease-causing genes, effectively knocking them down to provide potential treatments for conditions such as cardiovascular and metabolic diseases, immunology-related disorders, and diseases affecting the nervous system. By leveraging advanced RNA technology, Sanegene Bio is capable of achieving specific delivery of multiple RNA drugs, enhancing the effectiveness of its therapeutic offerings for patients suffering from a range of health issues, including infectious diseases and eye conditions.

XinjingZhiyuan is an immune cell therapy company focusing on solid tumors.

Allorion Therapeutics is a small molecule therapeutic development company specializing in the treatment of cancer and autoimmune diseases. With operations in Natick, Massachusetts, and Guangzhou, China, Allorion focuses on creating mutant selective and isoform-specific drugs through innovative methods targeting established medical challenges. By concentrating on enhancing drug efficacy and preventing resistance in patients, the company aims to improve therapeutic outcomes in these critical areas of healthcare.

AskGene Pharma is a biotechnology firm focused on developing innovative therapies for oncology and autoimmune diseases through its novel cytokine prodrug platform. This technology aims to unlock the full therapeutic potential of cytokine molecules, addressing significant challenges associated with current cytokine therapeutics. By avoiding systemic pharmacokinetic sinks and modulating specific immune cells within the tumor microenvironment, AskGene Pharma strives to deliver safer and more effective treatments. The company is dedicated to providing next-generation therapies to patients with critical unmet medical needs, leveraging advanced research and development facilities to advance its mission of improving patient outcomes.

UniXell Biotechnology is a developer of cell therapy focused on addressing unmet medical needs through human pluripotent stem cell technology. The company specializes in creating innovative treatments for neurodegenerative diseases, rare diseases, and tumors. Utilizing its proprietary platforms, UniXell Biotechnology has advanced capabilities in stem cell preparation, cultivation, differentiation, and gene editing. Key technologies include reprogramming techniques, stem cell differentiation, SISBAR pedigree tracing, and high-precision gene editing, which collectively aim to provide effective therapeutic solutions for patients suffering from challenging medical conditions.

UniXell develops cell therapies for the treatment of cancer and neurodegenerative disorders.

ChemSemi develops 5G chips and semiconductor technologies.

Hesguard is a medical device developer and producer of high-end implantable medical devices related to ophthalmic diseases.

Allorion Therapeutics is a small molecule therapeutic development company specializing in the treatment of cancer and autoimmune diseases. With operations in Natick, Massachusetts, and Guangzhou, China, Allorion focuses on creating mutant selective and isoform-specific drugs through innovative methods targeting established medical challenges. By concentrating on enhancing drug efficacy and preventing resistance in patients, the company aims to improve therapeutic outcomes in these critical areas of healthcare.

Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on designing and developing novel oral therapeutics to treat chronic diseases with high unmet need. Utilizing advanced computational and structure-based technology, the company creates life-changing medicines by integrating cutting-edge advancements in computational chemistry and molecular interaction visualization. Its pipeline includes GSBR-1290, an oral glucagon-like-peptide-1 receptor agonist for type-2 diabetes mellitus and obesity, as well as ANPA-0073 and LTSE-2578 targeting pulmonary and cardiovascular diseases respectively. The company's team, with deep experience in complex biological targets and structure-based drug design, aims to deliver efficacious and safe treatments with broad commercial potential.

Cellular Biomedicine Group, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company employs proprietary cell-based technologies, including various forms of CAR-T therapy, which targets different cancer types, and human adipose-derived mesenchymal progenitor cells aimed at treating joint diseases. Its product pipeline features therapies such as CD20 and CD22 CAR-T for B cell malignancies, and alpha fetoprotein TCR-T targeting hepatocellular carcinoma. Additionally, Cellular Biomedicine is developing knee osteoarthritis treatments, including AlloJoin and Re-Join, the latter having completed Phase IIb trials. The company also engages in broader biopharmaceutical activities, encompassing research and development, technical support, and manufacturing of pharmaceutical polypeptides and medical devices. It has established a partnership with Novartis Pharma AG to produce and supply the CAR-T cell therapy Kymriah in China. Founded in 2001, Cellular Biomedicine Group is headquartered in New York, New York, and draws on a wealth of cellular medicine research and expertise from scientists and clinicians across the United States, England, and China.

Coordination Pharmaceuticals is a drug development company that aims to address unmet medical needs and improve patient care. The NCP platform was pioneered by the lab of Professor Wenbin Lin at the University of Chicago. As a versatile technology platform, NCP components can be purposefully chosen to synergize with and enhance currently existing therapies. CPI products are especially potent in combination with checkpoint blockade inhibitors by increasing T cell infiltration into lowly immunogenic solid tumors.

CytoLynx Therapeutics is a R&D and commercial platform leveraging Cytovia’s unique technologies and product pipeline.

Etern is developing small molecule drugs for protein liquid-liquid phase separation, using the LLPS platform for AI-enabled target discovery, high-throughput screening, and optimization. This could open new treatment strategies for major diseases.

Abogen Biosciences, established in 2019 and headquartered in Jiangsu, China, specializes in the development of nucleic acid-based therapeutics, including RNA and DNA treatments, for combating cancer and infectious diseases.

Newsoara is a biomedical technology developer that specializes in the development of medical devices.

Regor Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for oncology, metabolic diseases, and autoimmune diseases. The company utilizes its proprietary CARD (Computer Accelerated Rational Discovery) platform, which integrates structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development to create clinically differentiated therapeutics. With a world-class scientific team, Regor Therapeutics is committed to efficiently producing both best-in-class and first-in-class molecules, advancing its mission to improve patient outcomes through novel therapeutic solutions.

QL Biopharma is engaged in the development of innovative and premium me-too drugs specifically aimed at treating chronic metabolic diseases. The company specializes in recombinant protein drugs that target conditions such as diabetes, obesity, and non-alcoholic fatty liver disease. By focusing on these therapeutic areas, QL Biopharma aims to enhance the quality of life for patients suffering from these prevalent health issues.

SciNeuro Pharmaceuticals is a biotechnology company based in Shanghai, China, focused on developing innovative medicines for patients with central nervous system (CNS) diseases. The company is committed to transforming the treatment landscape for these conditions through a robust product pipeline that emphasizes internal innovation and global collaboration. SciNeuro's drug development is guided by breakthrough scientific evidence, including insights from human genetics and pharmacology, targeting the underlying mechanisms of CNS diseases. By addressing these pathological mechanisms, SciNeuro aims to provide transformative therapies that not only aim to cure these diseases but also enhance the quality of life for patients.

Angitia Biopharmaceuticals is a global biotechnology company dedicated to the discovery and development of innovative therapeutics targeting serious musculoskeletal diseases. The company specializes in researching and developing breakthrough therapies for conditions affecting bones, muscles, and joints. By focusing on creating novel drugs, Angitia aims to provide effective treatments that enhance patient recovery from severe musculoskeletal ailments.

Hanyu Medical is a pioneering company in the development, production, and sale of transcatheter mitral valve repair devices. Specializing in minimally invasive treatments for mitral valve regurgitation, the company’s flagship product is the Valve Clamp, an interventional device designed to assist in the closure of heart valves during surgical procedures. By focusing on innovative solutions for heart valve diseases, Hanyu Medical aims to enhance surgical outcomes and patient recovery through its advanced medical technologies.

Ranok Therapeutics is a biotechnology company specializing in the development of innovative targeted protein degradation technology to facilitate the discovery and development of new therapeutics. This technology engages various biological processes and aims to surpass existing methods in the field. Ranok's research pipeline includes both established and novel drug targets that address cancer and other diseases with considerable unmet medical needs. The company is committed to creating the next generation of cancer therapies that prioritize safety and effectiveness for patients facing serious health challenges.

Oceanus Plus is a company based in China that specializes in the development of clinical trial management systems and clinical research products. The organization holds independent intellectual property rights, which allows it to innovate and tailor its offerings to meet the needs of the clinical research industry. Through its focus on enhancing the efficiency and effectiveness of clinical trials, Oceanus Plus aims to improve the overall quality of clinical research processes.

EOC Pharma Group is a biopharmaceutical company based in Shanghai, China, founded in 2015. It specializes in the development, manufacturing, and commercialization of innovative oncology products. EOC employs a licensing model to enhance its product pipeline by incorporating molecules from global biopharmaceutical partners into its robust local infrastructure, which includes manufacturing, clinical development, regulatory filing, and commercialization. The company has a diverse pipeline featuring seven novel products, several of which are positioned as potentially first- and best-in-class. EOC has achieved regulatory milestones with four Class I innovative drug approvals and has initiated clinical studies for its leading products. The company operates an 8,000 square meter cGMP manufacturing facility in Taizhou and maintains offices in key locations, including Shanghai, Beijing, Hong Kong, and Los Angeles. With a team of experienced professionals, EOC aims to establish itself as a leader in oncology innovation in China through strategic partnerships and a comprehensive integrated platform.

Shenzhen Tisenc Medical Devices Co., Ltd., established in 2015, is a Sino-foreign joint venture based in Shenzhen, Guangdong. The company specializes in the development, manufacturing, and global sales of chemiluminescence immunology systems and advanced diagnostic solutions. Tisenc focuses on creating automatic chemiluminescent analyzers and supporting diagnostic reagents, which are essential in the field of medical diagnostics and point-of-care testing. With over 16,000 square meters dedicated to research and development labs, a GMP factory, and an instrument manufacturing facility, Tisenc maintains full intellectual property rights for its products and technologies, ensuring independence in its research and production processes.

GeneQuantum Healthcare (Suzhou) Co., Ltd. is a high-tech company established in August 2013 in Suzhou Industrial Park, specializing in the research and development of innovative biotherapeutics. The company has developed a world-class bioconjugation technology platform that emphasizes the creation of next-generation anti-tumor Antibody-Drug-Conjugates (ADCs) with significant therapeutic potential. Utilizing a ligase-dependent conjugation platform, GeneQuantum enhances the therapeutic window for these drugs, allowing for advanced development in the field of oncology. The company is currently focused on advancing its ADC candidates toward Investigational New Drug (IND) filing in both the United States and China, while also expanding its product pipeline to address unmet medical needs in cancer treatment.

Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery, development, and manufacturing of innovative immuno-oncology therapies. Founded in 2016 by a team of experienced professionals from leading pharmaceutical companies, Abbisko is dedicated to developing small molecule inhibitors, including ABSK011 and ABSK021, for the treatment of hepatocellular carcinoma, as well as CSF1R for solid tumors. In addition to oncology, the company is engaged in developing therapeutics for various conditions, including cancer, liver diseases, diabetes, metabolic disorders, viral infections, and central nervous system diseases.

Zion Pharma is a prominent drug discovery platform specializing in the development of innovative small molecule drugs, primarily targeting oncology and tumor treatment. The company is dedicated to creating "me-better" drugs that address significant unmet medical needs, with a particular emphasis on differentiated "best-in-class" and "first-in-class" therapies. Zion Pharma's innovative drug pipeline includes a focus on breast cancer brain metastasis, enabling healthcare professionals to better meet clinical demands and improve patient outcomes. Through its commitment to addressing critical issues in cancer treatment, Zion Pharma positions itself as a key player in the pharmaceutical industry.

Antengene Corporation is a clinical-stage biopharmaceutical company based in Shanghai, China, founded in 2016. The company specializes in the development of innovative oncology therapies, focusing on treatments for various types of cancers, including hematologic malignancies and solid tumors. Antengene's product portfolio includes ATG-010 (selinexor), which targets XPO1 for treating multiple myeloma and DLBCL, and ATG-008 (onatasertib), an mTOR kinase inhibitor for advanced solid tumors. The company’s pipeline also features several compounds in various stages of development, such as ATG-016, ATG-527, ATG-019, and ATG-017, each targeting specific cancer pathways. In addition to its clinical programs, Antengene is involved in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics, aiming to address unmet medical needs in the oncology field across Asia.

BioNova Pharma biopharmaceutical company that develops and commercializes innovative medicines for cancer and other life-threatening diseases. The company is expanding company with a strong pipeline based on in-house R&D initiatives, partnerships with, and purchases from partners with cutting-edge technology. The goal of BioNova is to close the gap between the high unmet medical needs and the dearth of innovative medicines by developing an innovative R&D platform with a substantial pipeline to address multiple disease areas.

GenFleet Therapeutics, established in 2017 and headquartered in Shanghai, China, is a biotechnology company focused on cancer research and development. It specializes in creating therapeutic molecules, including signal transduction regulators, tumor microenvironment modulators, and transcription factors, to target various cancer systems. The company aims to develop innovative molecular-level pharmaceuticals and antibody drugs that can effectively stimulate the body's immune response against tumors. GenFleet serves both domestic and international clients.

Xgene Pharmaceutical Inc. is a pharmaceutical company founded in 2015 and based in the Cayman Islands. It focuses on developing small-molecule drugs aimed at treating chronic pain, infectious diseases, and tumors, with a particular emphasis on neurological disorders. As a late-clinical stage, venture-backed firm, Xgene utilizes proprietary linker technology to create novel, multimodal conjugated molecules. Its current programs are designed to enhance the efficacy and tolerability of pain medications, addressing unmet needs in the treatment of chronic pain and neurological conditions.

Eccogene is a clinical stage biopharmaceutical company focused on developing therapeutic solutions for unmet medical needs, particularly in the areas of metabolic and immune-related diseases. The company specializes in disease biology, medicinal chemistry, and translational science, with the aim of creating innovative pharmaceuticals that target complex chronic conditions such as obesity and diabetes. Eccogene is dedicated to advancing its pipeline of metabolic drugs to enhance patient outcomes and address significant health challenges.

Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on researching and developing innovative therapeutics. The company is primarily engaged in the clinical development of AZD3759, a small molecule tyrosine kinase inhibitor designed to treat patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) who have central nervous system metastases. Alpha Biopharma collaborates with prominent international pharmaceutical companies and utilizes a strong scientific consulting and management team to ensure rigorous research and development processes. The company emphasizes a multi-faceted approach to drug development, which includes research, market strategy, and intellectual property protection, while working closely with leading contract research organizations, contract manufacturing organizations, hospitals, and institutes to facilitate the orderly implementation of its projects.

Shenzhen Tisenc Medical Devices Co., Ltd., established in 2015, is a Sino-foreign joint venture based in Shenzhen, Guangdong. The company specializes in the development, manufacturing, and global sales of chemiluminescence immunology systems and advanced diagnostic solutions. Tisenc focuses on creating automatic chemiluminescent analyzers and supporting diagnostic reagents, which are essential in the field of medical diagnostics and point-of-care testing. With over 16,000 square meters dedicated to research and development labs, a GMP factory, and an instrument manufacturing facility, Tisenc maintains full intellectual property rights for its products and technologies, ensuring independence in its research and production processes.

Founded in 2015, Xpect Vision Technology is a high-tech company specializing in the development of innovative imaging technology, particularly photon-counting X-ray imaging. The company manufactures medical imaging chips designed for the medical detection and service industry, utilizing advanced digital X-ray imaging technology and CMOS X-ray detection methods. These imaging chips are integrated into medical electronic products, enabling physicians to enhance the accuracy of cancer diagnoses and improve overall efficiency in medical services. Xpect Vision is positioned to lead future developments in high-speed and high-definition imaging solutions.

Xgene Pharmaceutical Inc. is a pharmaceutical company founded in 2015 and based in the Cayman Islands. It focuses on developing small-molecule drugs aimed at treating chronic pain, infectious diseases, and tumors, with a particular emphasis on neurological disorders. As a late-clinical stage, venture-backed firm, Xgene utilizes proprietary linker technology to create novel, multimodal conjugated molecules. Its current programs are designed to enhance the efficacy and tolerability of pain medications, addressing unmet needs in the treatment of chronic pain and neurological conditions.

Antengene Corporation is a clinical-stage biopharmaceutical company based in Shanghai, China, founded in 2016. The company specializes in the development of innovative oncology therapies, focusing on treatments for various types of cancers, including hematologic malignancies and solid tumors. Antengene's product portfolio includes ATG-010 (selinexor), which targets XPO1 for treating multiple myeloma and DLBCL, and ATG-008 (onatasertib), an mTOR kinase inhibitor for advanced solid tumors. The company’s pipeline also features several compounds in various stages of development, such as ATG-016, ATG-527, ATG-019, and ATG-017, each targeting specific cancer pathways. In addition to its clinical programs, Antengene is involved in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics, aiming to address unmet medical needs in the oncology field across Asia.

TongliBio is a biotechnology company focused on developing innovative medical products to address unmet medical needs, particularly in the realm of tropical diseases. The company engages in the discovery of new drugs and translational medicine, conducting pioneering preclinical and clinical research on anti-infectious agents. Additionally, TongliBio utilizes proprietary chemoenzymatic process technology to promote green pharmaceutical manufacturing, striving to deliver affordable and high-quality medical solutions for infectious diseases.

GeneQuantum Healthcare (Suzhou) Co., Ltd. is a high-tech company established in August 2013 in Suzhou Industrial Park, specializing in the research and development of innovative biotherapeutics. The company has developed a world-class bioconjugation technology platform that emphasizes the creation of next-generation anti-tumor Antibody-Drug-Conjugates (ADCs) with significant therapeutic potential. Utilizing a ligase-dependent conjugation platform, GeneQuantum enhances the therapeutic window for these drugs, allowing for advanced development in the field of oncology. The company is currently focused on advancing its ADC candidates toward Investigational New Drug (IND) filing in both the United States and China, while also expanding its product pipeline to address unmet medical needs in cancer treatment.

Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery, development, and manufacturing of innovative immuno-oncology therapies. Founded in 2016 by a team of experienced professionals from leading pharmaceutical companies, Abbisko is dedicated to developing small molecule inhibitors, including ABSK011 and ABSK021, for the treatment of hepatocellular carcinoma, as well as CSF1R for solid tumors. In addition to oncology, the company is engaged in developing therapeutics for various conditions, including cancer, liver diseases, diabetes, metabolic disorders, viral infections, and central nervous system diseases.

Asieris Pharmaceuticals Co. Ltd. is a biotechnology company based in Taizhou, China, founded in 2010. The company is dedicated to the research and development of pharmaceutical products aimed at treating tumors and addressing multidrug-resistant infections. By focusing on oncology and infectious diseases, Asieris Pharmaceuticals seeks to develop innovative therapies that meet the medical needs of patients both in China and globally.

Hua Medicine, established in 2009, is a Shanghai-based clinical-stage drug development company. It specializes in therapies for diabetes and central nervous system (CNS) disorders in China. The company's primary focus is Dorzagliatin, an oral drug for Type 2 diabetes, which is in Phase 3 clinical trials, both as a standalone treatment and in combination with metformin. Additionally, Hua Medicine is developing Dorzagliatin in combination with other drugs and mGLUR5 for Parkinson's disease levodopa-induced dyskinesia, both in pre-clinical stages. The company's mission is to address unmet medical needs in China through innovative drug development.

Zai Lab Limited is a biopharmaceutical company based in Shanghai that focuses on discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. Founded in 2013, the company has established a diverse pipeline of proprietary drug candidates, including Niraparib for various solid tumors, Ripretinib for KIT and PDGFRa-driven cancers, and Margetuximab for breast and gastric cancers. Zai Lab also develops antibiotics such as Omadacycline and Durlobactam for bacterial infections. The company seeks to address unmet medical needs in China and globally by leveraging partnerships with leading biopharmaceutical firms and utilizing its in-house manufacturing capabilities. Zai Lab aims to establish itself as a fully integrated biopharmaceutical entity, enhancing its drug development efforts through collaborations with academic institutions and expanding its commercial reach in the Chinese market.

Wecare Probiotics is a national high-tech enterprise focused on the research and development, production, and application of probiotic strains. The company offers a diverse range of probiotic products, including fermented food strains and beneficial microbial flora, suitable for various industries such as food, healthcare, and medicine. By prioritizing quality and efficiency, Wecare Probiotics aims to deliver effective solutions that meet the needs of its customers.

Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of therapeutics aimed at addressing unmet medical needs, particularly in the areas of respiratory viral infections and viral hepatitis. Founded in 2013, the company focuses on developing innovative treatments, including AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences is committed to advancing antiviral drug research and development to serve both global and Chinese markets.

Hua Medicine, established in 2009, is a Shanghai-based clinical-stage drug development company. It specializes in therapies for diabetes and central nervous system (CNS) disorders in China. The company's primary focus is Dorzagliatin, an oral drug for Type 2 diabetes, which is in Phase 3 clinical trials, both as a standalone treatment and in combination with metformin. Additionally, Hua Medicine is developing Dorzagliatin in combination with other drugs and mGLUR5 for Parkinson's disease levodopa-induced dyskinesia, both in pre-clinical stages. The company's mission is to address unmet medical needs in China through innovative drug development.

CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.

Zai Lab Limited is a biopharmaceutical company based in Shanghai that focuses on discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. Founded in 2013, the company has established a diverse pipeline of proprietary drug candidates, including Niraparib for various solid tumors, Ripretinib for KIT and PDGFRa-driven cancers, and Margetuximab for breast and gastric cancers. Zai Lab also develops antibiotics such as Omadacycline and Durlobactam for bacterial infections. The company seeks to address unmet medical needs in China and globally by leveraging partnerships with leading biopharmaceutical firms and utilizing its in-house manufacturing capabilities. Zai Lab aims to establish itself as a fully integrated biopharmaceutical entity, enhancing its drug development efforts through collaborations with academic institutions and expanding its commercial reach in the Chinese market.

Shanghai Sanyou Medical Co., Ltd., based in Shanghai, specializes in the research, development, manufacturing, and sales of orthopedic implants in China. The company offers a range of products under the Tytus and Sanyou brands, including spinal implants like anterior cervical plates, posterior thoracolumbar systems, and minimally invasive products, as well as trauma implants for shoulders, elbows, hips, knees, and wrists. Established in 2010, the company is committed to independent innovation and has a senior international management team.